Rheumatology (conditions continued) Flashcards
Systemic lupus erythematosus (SLE)
- is a multisystem autoimmune disease of unknown aetiology that can present at any age.
- SLE is prone to relapses and remissions and can result in morbidity due to flares of disease activity and accumulating damage over time, along with an increased risk of premature death due to infection or cardiovascular disease.
Lupus erythematosus describes the typical rash seen in SLE. The “systemic” part indicates the potential for multi-organ involvement.
Antiphospholipid syndrome can happen secondary to SLE, which carries an increased risk of venous thromboembolism.
SLE pathophysiology
Pathophysiology
SLE is thought to be a type III hypersensitivity reaction where impaired clearance of dead cells and failure of processes giving immune tolerance to nuclear antigens may lead to the development of antibodies against double-stranded DNA and nuclear proteins.
RF for SLE
* female
* >30
* African-caribbean descent
* Drugs e.g. sulfasalazine, phenytoin
* family history
* smoking
SLE is associated with
- Antiphospholipid syndrome
- RA
- Other autoimmune e.g. thyroiditis
- Atherosclerosis/HTN/dyslipidaemia, diabetes, osteo
- Non-hodgkins lymphoma
presentation of SLE
General
- Fever
- Fatigue
- Lymphadenopathy
- Mouth ulcers
Skin and hair
- Butterfly rash
- Photosensitive rash
- DIscoid rashes
- Raynauds
- Alopecia
- Vasculitis rashes
MSK
- Myalgia
- Arthritis
Pulmonary
- Pleurisy
- alveolitis
- PE (antiphospholipid association)
Cardiovascular
- Pericarditis
- HTN
- Myocardiits
Renal
- Protien uria, haematuira, HTN
Neuropsychiarric symptoms
- Anxiety
- Depression
- Psychosis
- Seizures
- Strokes secondary to vascultiis
Antibodies for SLE
Common
- ANA (high sensitivity)- all patients with SLE will have this, but some without will also have it
- Anti-dsDNA (high specificity) - patients with SLE will defo have this
Others
Anti-Smith, anti-Ro (SS-A), and anti-La (SS-B)
Monitoring disease activity: SLE
- Erythrocyte sedimentation rate (ESR) is used
- C-reactive protein (CRP) may be normal during active disease
- If CRP is raised, this may indicate an underlying infection
- C3 and C4 may be low in active disease
investigations for SLE
Autoantibodies
- ANA
- anti-dsDNA
FBC
- anaemia, leukopeia, thrombocytopenia
APTT
- prolonged if antiphospholipid sydnrome - think VTE
UE
- renal manifeststions e.g. glomerulonephritis
- calcium can be high
Urinalysis
- haematuria
- casts
- proteinuria
CXR
- pleural effusion
- inflitrates
- cardiomegaly
ECG
- chest pain - rule out cardiopulmonary symptoms
Antiphospholipid antibodies
- venous thromboembolism
- recurrent miscarriages
- prolonged APTT
management of SLE
First line
- NSAIDS for MSK pain and headaches e.g. naproxen (PPI)
- Sunscreen
Second line
- Hydroxychloroquine
advice to patients with SLE
- Patients should avoid excessive sun exposure and use effective sun screen
- Patients should be aware that some drugs can exacerbate SLE
- Patients should have smoking cessation help and aim to stop
- Oestrogen-containing hormonal contraception can worsen SLE, but the lowest dose can cautiously be used if there are no contraindications and no anticardiolipin antibodies present
- Fertility is normal and pregnancy is safe in stable/mild SLE
- If SLE is severe, pregnancy should be delayed until the disease is better controlled:
drug-induced lupus vs SLE
- Drug-induced lupus (DIL) is an autoimmune condition where a patient develops signs and symptoms similar to systemic lupus erythematosus after exposure to certain drugs.
- DIL carries a more favourable prognosis compared to SLE and resolves within a few weeks after discontinuing the offending drug.
causes of drug induced lupus
Drug Causes
- Procainamide
- Hydralazine
- Minocycline
- Terbinafine
- Sulfasalazine
- Isoniazid
- Phenytoin
- Carbamazepine
investigations for drug induced lupus
Anti-nuclear antibodies (ANA):
* Nearly positive in all patients
Anti-double-stranded DNA (anti-dsDNA):
* Absent in most patients, used to screen for SLE
Anti-histone antibodies:
* Present in up to 90% of patients
antiphospholipid syndrome
an autoimmune disorder characterised by:
* arterial and venous thrombosis,
* adverse pregnancy outcomes
* raised levels of antiphospholipid (aPL) antibodies.
antiphospholipid syndrome can occur secondary to
SLE or other autoimmune conditions
antiphospholipids associations
- 30% of people who have systemic lupus erythematosus have aPL antibodies
- Higher prevalence in black people
- Most seen in young women of childbearing age with a male: female ratio of 1:3.5
- Accounts for 20% of recurrent thrombosis in young people
- Accounts for 15% of cases of recurrent foetal loss
presentation of antiphospholipid syndrome
- Recurrent foetal loss
- Features of thrombocytopenia:
- Petechial rashes
- Mucosal bleeding
- Arthralgia
- Due to possible underlying systemic lupus erythematosus
- Livedo reticularis
- Coagulation assays show a prolonged APTT
- Pulmonary hypertension
- Pregnancy morbidity:
- Pre-eclampsia
- Placental abruption
- Intrauterine growth restriction
Investigations for antiphospholipid syndrome
Autoantibodies
1) If associated with SLE: ANA and anti-dsDNA antibodies
2) Any of these positive/elevated on 2 occasions 12 weeks apart:
- Lupud anticoagulant
- Anticardiolipin antibodies
- Anti-beta2-glycoprotein I antibodies
Coagulation assays
- Prolonged APTT
Others
- Full blood count - thrombocytopenia
- Venous doppler US - if DVT suspected
- CTPAor V/Q scan - if PE suspected
-
diagnosing antiphospholipid syndrome
The diagnosis of APS requires at least 1 clinical criterionand 1 laboratory criterion.
Clinical criteria are:
- 1 or more episodes of vascular thrombosis
- 1 or more unexplained losses of morphologically normal foetuses at or beyond the 10th week of gestation
Laboratory criteria are (must be positive on 2 or more occasions at least 12 weeks apart):
- Lupus anticoagulant present
- Anticardiolipin antibody present
- Anti-beta2-glycoprotein I antibody
management of antiphospholipid syndrome: Non-pregnant patients
2 scenarios
1) No previous VTE: low dose aspirin
2) Single VTE episode: life long warfarin
- initially aim for an INR of 2-3
- if recurrent: increase INR to 3-4 and consider adding low-dose aspirin
management of antiphospholipid syndrome: pregnant patients
Different stages:
Stage 1
* Low-dose aspirin once the pregnancy is confirmed via urinary beta-hCG testing
Stage 2
* Low molecular weight heparin (LMWH) once the foetal heart is seen on ultrasound until 34 weeks gestation when it is then stopped
Stage 3
* Return to warfarin (teratogen) post-delivery
Systemic sclerosis
a multisystem autoimmune disease leading to increased fibroblast activity causing abnormal growth of connective tissue -> this leads to vascular damage and fibrosis:
- Skin
- GI tract
- Heart
- Lungs
-
There are three main patterns of SSc:
- Limited cutaneous SSc (lcSSc)
- Diffuse cutaneous SSc (dcSSc)
- Scleroderma
presentation of limited cutaneous systemic sclerosis (lcSSc) (limited systemic scleroderma)
most common type - commonly affecting face and distal limbs
CREST syndrome features
- Calcinosis
- Raynaud’s disease
- (O)Esophageal dysmotility and gastro-oesophageal reflux (GORD)
- Sclerodactyly
- Telangiectasia
Diffuse cutaneous systemic sclerosis (dcSSC) (diffuse scleroderma)
Less common- commonly affecting the trunk and proximal limbs
- Usually more rapid onset with skin thickening and Raynaud’s phenomenon happening together or with a short interval
- Internal organ involvement more common such as interstitial lung disease
Presentation of diffuse cutaneous systemic sclerosis
Diffuse cutaneous systemic sclerosis includes the CREST features and also affects internal organs, causing:
- Cardiovascular problems (e.g., hypertension and coronary artery disease)
- Lung problems (e.g., pulmonary hypertension and pulmonary fibrosis)
- Kidney problems (e.g., glomerulonephritis and scleroderma renal crisis)